secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034829
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports Q3 revenue $72.4M, net loss $8.1M; signs Dynavax COVID-19 pill license deal worth up to $700M
--------------------------------------------------------------------------------

- Revenue $72.4M (vs $4.9M Q3 2024) from BARDA contract; net loss $8.1M ($0.04 EPS) vs $14.1M loss.
- Exclusive license with Dynavax: $25M upfront + $5M equity; up to $700M in milestones and royalties.
- Phase 2b COVID-19 trial enrollment completed (~5,400); topline data expected late 2026, sentinel cohort Q1 2026.
- Cash, equivalents, investments $28.8M; with Dynavax payment runway extended to Q2 2027.
- Phase 1 norovirus oral vaccine data shows robust fecal IgA; partnership discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/0001437749-25-034829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/vxrt20251112c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer